

Special Issue

Role of MicroRNAs and Long Non-coding RNAs in Sjögren's Syndrome

Message from the Guest Editor

Sjögren's Syndrome (SS) is a chronic autoimmune inflammatory disease, characterized by chronic lymphocytic infiltrates in the exocrine glands, in particular lacrimal and salivary glands, causing dryness. Among the mechanism of epigenetic regulation involved in SS development, emerging data support the role of non-coding RNAs (ncRNAs). ncRNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), are a cluster of RNAs that do not encode functional proteins, but play critical roles in the post-transcriptional gene expression. Although the advent of high throughput technologies and the availability of public databases have facilitated the recognition of the complicated interplay among lncRNAs, miRNAs and target genes, their role has not been comprehensively studied in SS. Further research is required to better understand the molecular mechanisms involved in the regulation of these non-coding RNAs.

The aim of this Special Issue is to highlight recent advances in the context of role of miRNAs and lncRNAs in Sjögren's Syndrome.

Guest Editor

Dr. Andrea Latini

Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy

Deadline for manuscript submissions

closed (31 August 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/164507

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).